Published Studies Related to Cabergoline
Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia. [2010.11]
OBJECTIVE: This study aimed to determine the effectiveness of short-term maintenance treatment with cabergoline and to find out minimum effective dosage of cabergoline during maintenance treatment for patients with microadenoma-related and idiopathic hyperprolactinemia... CONCLUSIONS: The results indicate that short maintenance treatment in idiopathic and microadenoma-related hyperprolactinemia seems as effective as long maintenance treatment in the present study. But, further studies with larger study population and longer follow-up period are needed to make a decision about early treatment withdrawal. Also, during the maintenance treatment administration of medicine to patients should be tapered down to the lowest dose that will maintain prolactin levels normal.
Cabergoline versus bromocriptine for symptomatic treatment of premenstrual mastalgia: a randomised, open-label study. [2010.06]
OBJECTIVE: To compare the effectiveness and side effects of cabergoline with bromocriptine for the symptomatic treatment of cyclic mastalgia as a part of the premenstrual syndrome... CONCLUSIONS: Cabergoline is as effective as bromocriptine for the treatment of cyclic mastalgia but has minimal side effects compared to bromocriptine. Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
A comparison of bromocriptine & cabergoline on fertility outcome of hyperprolactinemic infertile women undergoing intrauterine insemination. [2010.05]
BACKGROUND & OBJECTIVES: The aim of this study was to compare the effects of bromocriptine versus cabergoline on pregnancy in hyperprolactinaemic infertile women... CONCLUSION: Our results suggest that cabergoline treatment in infertile women with prolactinemia is more effective. It lowers prolactin with better tolerability and much more effective in the achievement of pregnancy.
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. [2007.08]
CONTEXT: Ovarian hyperstimulation syndrome (OHSS) results from increased vascular permeability (VP) caused by ovarian hypersecretion of vascular endothelial growth factor (VEGF), which activates its receptor-2. In animals, the dopamine receptor 2 agonist cabergoline (Cb2) inactivates VEGF receptor-2 and prevents increased VP. OBJECTIVE: Our objective was to test whether Cb2 reduces VP and prevents OHSS in humans... CONCLUSIONS: Given that Cb2 is a well-established and safe medication, this study provides proof of concept for the use of dopamine agonists in the prevention of OHSS in women undergoing assisted reproduction.
Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial. [2007.04.15]
We report the first large-scale double-blind, randomly assigned study to compare two active dopaminergic therapies for Restless Legs Syndrome (RLS), the dopamine agonist cabergoline (CAB) and levodopa/benserazide (levodopa). Patients with idiopathic RLS were treated with fixed daily doses of 2 or 3 mg CAB or 200 or 300 mg levodopa for 30 weeks...
Clinical Trials Related to Cabergoline
A Pilot Study of Cabergoline for the Treatment of Cocaine Dependence [Completed]
The purpose of this study is to determine the effects of treatment with cabergoline,
compared to treatment with placebo, on cocaine induced craving and subjective effects in
cocaine-dependent human volunteers.
Efficacy of Rapid Escalation of Cabergoline in Comparison to Conventional Dosing in Prolactin Secreting Macroadenomas. [Recruiting]
Cabergoline Versus GnRH Antagonist Rescue and Cabergoline in the Prevention of Ovarian Hyperstimulation Syndrome [Recruiting]
The aim of study is to compare the efficacy of GnRH antagonist rescue combined with
cabergoline with cabergoline in the prevention of ovarian hyperstimulation syndrome in
high risk patients undergoing ovarian stimulation for IVF-ET with long GnRH agonist
Cabergoline and Hydroxyethyl Starch in Ovarian Hyperstimulation Syndrome Prevention [Completed]
The purpose of this study is to assess whether, in GnRH agonist in vitro fertilization (IVF)
cycles, where there is a risk of ovarian hyperstimulation syndrome (OHSS), the addition of
cabergoline to the hydroxyethyl starch infusion could decrease OHSS incidence and severity.
Diosmin Versus Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome [Completed]
The purpose of this study is to compare the effect of oral Diosmin to oral Cabergoline in
the prevention of ovarian hyperstimulation syndrome (OHSS) in high-risk women underwent
intracytoplasmic sperm injection (ICSI).
Reports of Suspected Cabergoline Side Effects
Neoplasm Progression (9),
Visual Pathway Disorder (9),
Drug Interaction (8),
Pathological Gambling (6),
Psychiatric Symptom (6),
Visual Field Defect (6),
Drug Ineffective (5),
Hypersexuality (5), more >>